Experimental combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT03011814
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests a drug called durvalumab, given alone or with lenalidomide, in people with T-cell lymphoma that returned or didn't respond to prior treatments. The goal is to find the best dose and see how well the combination works. About 38 adults with certain types of T-cell lymphoma are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MYCOSIS FUNGOIDES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.